Khondrion announces first patients dosed in KHENEREXT Phase IIb extension study
Khondrion announces first patients dosed in KHENEREXT Phase IIb extension study examining long-term safety and efficacy of oral sonlicromanol in mitochondrial disease patients Enabling continued treatment in 52-week multi-centre study for patients who